Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Heidi J SilverDianna OlsonDustin MayfieldPatricia WrightHui NianMona MashayekhiJohn R KoetheKevin D NiswenderJames M LutherNancy J BrownPublished in: Diabetes, obesity & metabolism (2023)
Although both liraglutide and CR are valuable strategies for cardiometabolic risk reduction, CR was associated with greater weight loss and more favourable improvements in body composition than treatment with liraglutide alone. Differences in the response to each of these interventions enables patients to be stratified to the most optimal intervention for their personal risk factors.
Keyphrases
- weight loss
- body composition
- risk factors
- end stage renal disease
- bariatric surgery
- chronic kidney disease
- roux en y gastric bypass
- ejection fraction
- resistance training
- type diabetes
- metabolic syndrome
- insulin resistance
- bone mineral density
- randomized controlled trial
- newly diagnosed
- physical activity
- peritoneal dialysis
- gastric bypass
- prognostic factors
- weight gain
- body mass index
- skeletal muscle
- patient reported outcomes
- high fat diet induced
- body weight
- smoking cessation
- adipose tissue